Satsuma Pharmaceuticals, Inc. Common Stock

STSA

Valor de mercado US$ 36,5 mi

Sobre: Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

Funcionários: 25